Edition:
United Kingdom

Horizon Pharma PLC (HZNP.OQ)

HZNP.OQ on NASDAQ Stock Exchange Global Select Market

14.68USD
12 Dec 2017
Change (% chg)

$-0.09 (-0.61%)
Prev Close
$14.77
Open
$14.78
Day's High
$14.99
Day's Low
$14.68
Volume
483,260
Avg. Vol
784,892
52-wk High
$18.30
52-wk Low
$9.45

Latest Key Developments (Source: Significant Developments)

Horizon Pharma reports Q3 Non-GAAP earnings per share $0.26
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Horizon Pharma Plc : :Horizon Pharma plc announces third-quarter and year-to-date 2017 results.Q3 sales $271.6 million versus I/B/E/S view $259.7 million.Q3 earnings per share view $0.22 -- Thomson Reuters I/B/E/S.Sees FY 2017 sales $1.03 billion to $1.05 billion.Q3 GAAP loss per share $0.39.Q3 Non-GAAP earnings per share $0.26.Horizon Pharma plc says sees FY 2017 ‍adjusted EBITDA guidance range of $350 million to $375 million from $340 million to $375 million.Horizon Pharma says sees Krystexxa 2018 net sales up more than 50 percent​.  Full Article

Horizon pharma plc announces Q3 non-gaap earnings per share $0.26
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Horizon Pharma PLC :Horizon Pharma PLC announces third-quarter and year-to-date 2017 results.Q3 Non-GAAP earnings per share $0.26.Q3 sales $271.6 million versus I/B/E/S view $259.7 million.Q3 earnings per share view $0.22 -- Thomson Reuters I/B/E/S.Sees FY 2018 sales up more than 50 percent.Sees FY 2017 sales $1.03 billion to $1.05 billion.Q3 gaap loss per share $0.39.Horizon Pharma PLC - sees FY 2017 ‍adjusted EBITDA guidance range of $350 million to $375 million from $340 million to $375 million​.  Full Article

Horizon Pharma says first patient enrolled in confirmatory Phase 3 clinical trial evaluating Teprotumumab
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Horizon Pharma Plc :Horizon Pharma Plc announces first patient enrolled in confirmatory Phase 3 clinical trial evaluating Teprotumumab for the treatment of moderate-to-severe active thyroid eye disease.  Full Article

Horizon Pharma borrows $845.8 mln principal amount of loans
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Horizon Pharma Plc -:Horizon Pharma - co, units borrowed $845.8 million principal amount of loans pursuant to amendment to credit agreement dated as of may 7, 2015-sec filing​.  Full Article

Horizon Pharma raises full-year 2016 net sales guidance
Tuesday, 25 Oct 2016 

Horizon Pharma Plc : Horizon Pharma plc - raises full-year 2016 net sales guidance and confirms full-year 2016 adjusted ebitda guidance . Horizon Pharma plc sees full-year 2016 net sales approximately $980 to $985 million . Horizon Pharma - raising net sales guidance on a non-GAAP adjusted basis to approximately $1.045 to $1.050 billion excluding $65 million settlement for fy .Fy2016 revenue view $1.03 billion -- Thomson Reuters I/B/E/S.  Full Article

Horizon Pharma announces proposed private offering of senior notes
Thursday, 13 Oct 2016 

Horizon Pharma Plc : Horizon Pharma Plc announces proposed private offering of senior notes and intention to borrow incremental term loans under its existing senior secured credit facility . Horizon Pharma subsidiaries to offer $300 million aggregate principal amount of senior notes due 2024 . Horizon Pharma units to borrow $375 million aggregate principal amount of incremental term loans under Horizon's existing senior secured credit facility .Horizon Pharma expects to use net proceeds from offering and incremental term loans to fund a portion of Horizon's planned acquisition of Raptor Pharma.  Full Article

Horizon Pharma says unit enters into settlement deal with Express Scripts - SEC filing
Thursday, 29 Sep 2016 

Horizon Pharma PLC : On Sept 26, Horizon Pharma USA entered settlement agreement and mutual release with Express Scripts to settle litigation - SEC filing . 25 percent of settlement amount will be paid to Express Scripts in Q1 of 2017 and 25 percent in Q2 of 2017 . Horizon Pharma's discussions with Express Scripts regarding DUEXIS and VIMOVO on its formulary exclusion list are ongoing . Settlement amount will be paid to Express Scripts in installments, with 50 percent of installment paid in Q4 of 2016 . Expects that settlement payment will be recorded as a reduction in GAAP net sales in Q3 of fiscal 2016 .Continues its discussions and negotiations with other pharmacy benefit managers and payers.  Full Article

Horizon pharma Q2 diluted earnings per share $0.09
Monday, 8 Aug 2016 

Horizon Pharma Plc : Horizon Pharma Plc announces second-quarter 2016 financial results . Sees FY 2016 sales $1.025 billion to $1.05 billion . Q2 sales $257.4 million versus I/B/E/S view $234.9 million . Qtrly earnings per share - diluted $0.09 . Qtrly non-GAAP earnings per share - diluted $0.62 .Confirms full-year 2016 net sales guidance of $1.025 to $1.050 bln and full-year 2016 adjusted EBITDA guidance of $495 to $510 mln.  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Tuesday, 2 Aug 2016 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

BRIEF-Horizon Pharma Names Shao-Lee Lin Chief Scientific Officer

* HORIZON PHARMA PLC NAMES SHAO-LEE LIN, M.D., PH.D. EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT AND CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage: